Collegium Pharmaceutical, Inc. Common Stock (COLL)
Collegium Pharmaceutical, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines for patients with serious medical needs. It is known for its opioid receptor modulators and other pain management therapies, integrating science and technology to address pain treatment challenges.
Company News
Collegium Pharmaceutical, Inc. announced it will have two poster presentations highlighting real-world data from its ADHD treatment, Jornay PM, at the National Association of Pediatric Nurse Practitioners National Conference.
Throughout the last three months, 4 analysts have evaluated Collegium Pharmaceutical (NASDAQ:COLL), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts have set 12-month price targets for Collegium Pharmaceutical, revealing an average target of $39.5, a high estimate of $40.00, and a low estimate of $39.00. Surpassing the previous average price target of $37.67, the current average has increased by 4.86%. Interpreting Analyst Ratings: A Closer Look The standing of Collegium Pharmaceutical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Amsellem Piper Sandler Maintains Neutral $39.00 $39.00 Serge Belanger Needham Maintains Buy $40.00 - Les Sulewski Truist Securities Raises Buy $40.00 $37.00 David Amsellem Piper Sandler Raises Overweight $39.00 $37.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Collegium Pharmaceutical. This insight gives a snapshot of ...Full story available on Benzinga.com
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Small-cap stocks offer high growth but come with risk. Quant Ratings can find high-growth small-caps with solid fundamentals. Click here for 10 Small-Cap Stocks.